Reviva Non Current Liabilities Total vs Cash And Short Term Investments Analysis

RVPH Stock

USD 1.14 0.02 1.79%

Reviva Pharmaceuticals financial indicator trend analysis is much more than just breaking down Reviva Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Reviva Pharmaceuticals is a good investment. Please check the relationship between Reviva Pharmaceuticals Non Current Liabilities Total and its Cash And Short Term Investments accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Non Current Liabilities Total vs Cash And Short Term Investments

Non Current Liabilities Total vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Reviva Pharmaceuticals Non Current Liabilities Total account and Cash And Short Term Investments. At this time, the significance of the direction appears to have pay attention.

The correlation between Reviva Pharmaceuticals' Non Current Liabilities Total and Cash And Short Term Investments is -0.98. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Reviva Pharmaceuticals Holdings, assuming nothing else is changed. The correlation between historical values of Reviva Pharmaceuticals' Non Current Liabilities Total and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Reviva Pharmaceuticals Holdings are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Non Current Liabilities Total i.e., Reviva Pharmaceuticals' Non Current Liabilities Total and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.98

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Non Current Liabilities Total

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Reviva Pharmaceuticals balance sheet. This account contains Reviva Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Reviva Pharmaceuticals Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Reviva Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

As of now, Reviva Pharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Reviva Pharmaceuticals' current Enterprise Value is estimated to increase to about 104.2 M, while Tax Provision is projected to decrease to 9,973.

	2021	2023	2024 (projected)
Depreciation And Amortization	1.6M	223.9K	212.7K
Interest Income	182.8K	499.0K	523.9K

Depreciation And Amortization Interest Income

Reviva Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Other Current Liab		0.93	0.53	-0.91	0.77	0.29	0.51	0.69	-0.42	0.55	-0.95	0.33	-0.95	-0.63	0.56	-0.64	-0.95	0.56	0.56	0.66	-0.95	-0.54	0.8	0.92	0.42	0.62
Total Current Liabilities	0.93		0.28	-0.85	0.73	0.04	0.27	0.59	-0.24	0.32	-0.9	0.06	-0.9	-0.4	0.33	-0.48	-0.9	0.33	0.34	0.56	-0.9	-0.36	0.73	1.0	0.16	0.4
Net Tangible Assets	0.53	0.28		-0.72	0.75	0.77	0.95	0.82	-0.84	0.96	-0.5	0.95	-0.5	-0.98	0.97	-0.94	-0.5	0.97	0.95	0.84	-0.5	-0.95	0.72	0.26	0.99	0.98
Retained Earnings	-0.91	-0.85	-0.72		-0.96	-0.38	-0.69	-0.89	0.62	-0.72	0.86	-0.52	0.86	0.79	-0.73	0.84	0.86	-0.73	-0.76	-0.87	0.86	0.77	-0.93	-0.84	-0.63	-0.8
Accounts Payable	0.77	0.73	0.75	-0.96		0.33	0.68	0.89	-0.68	0.71	-0.77	0.55	-0.77	-0.79	0.73	-0.86	-0.77	0.73	0.8	0.88	-0.77	-0.8	0.86	0.72	0.68	0.84
Other Assets	0.29	0.04	0.77	-0.38	0.33		0.88	0.53	-0.56	0.88	-0.22	0.9	-0.22	-0.82	0.86	-0.76	-0.22	0.86	0.62	0.64	-0.22	-0.8	0.53	0.03	0.8	0.63
Total Current Assets	0.51	0.27	0.95	-0.69	0.68	0.88		0.85	-0.79	1.0	-0.41	0.95	-0.41	-0.97	1.0	-0.95	-0.41	1.0	0.91	0.89	-0.41	-0.98	0.79	0.26	0.95	0.89
Common Stock	0.69	0.59	0.82	-0.89	0.89	0.53	0.85		-0.73	0.85	-0.55	0.66	-0.55	-0.85	0.86	-0.9	-0.55	0.86	0.9	0.98	-0.55	-0.9	0.96	0.57	0.77	0.84
Property Plant Equipment	-0.42	-0.24	-0.84	0.62	-0.68	-0.56	-0.79	-0.73		-0.79	0.38	-0.76	0.38	0.8	-0.79	0.78	0.38	-0.79	-0.85	-0.72	0.38	0.8	-0.62	-0.2	-0.83	-0.84
Total Assets	0.55	0.32	0.96	-0.72	0.71	0.88	1.0	0.85	-0.79		-0.47	0.95	-0.47	-0.99	1.0	-0.96	-0.47	1.0	0.91	0.9	-0.47	-0.98	0.8	0.3	0.96	0.91
Short Long Term Debt Total	-0.95	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.55	0.38	-0.47		-0.32	1.0	0.59	-0.48	0.61	1.0	-0.48	-0.46	-0.55	1.0	0.49	-0.65	-0.89	-0.39	-0.61
Total Stockholder Equity	0.33	0.06	0.95	-0.52	0.55	0.9	0.95	0.66	-0.76	0.95	-0.32		-0.32	-0.93	0.94	-0.88	-0.32	0.94	0.83	0.73	-0.32	-0.91	0.57	0.05	0.97	0.87
Current Deferred Revenue	-0.95	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.55	0.38	-0.47	1.0	-0.32		0.59	-0.48	0.61	1.0	-0.48	-0.46	-0.55	1.0	0.49	-0.65	-0.89	-0.39	-0.61
Net Debt	-0.63	-0.4	-0.98	0.79	-0.79	-0.82	-0.97	-0.85	0.8	-0.99	0.59	-0.93	0.59		-0.99	0.98	0.59	-0.99	-0.91	-0.89	0.59	0.98	-0.8	-0.39	-0.96	-0.95
Cash	0.56	0.33	0.97	-0.73	0.73	0.86	1.0	0.86	-0.79	1.0	-0.48	0.94	-0.48	-0.99		-0.97	-0.48	1.0	0.92	0.9	-0.48	-0.98	0.81	0.31	0.96	0.92
Non Current Assets Total	-0.64	-0.48	-0.94	0.84	-0.86	-0.76	-0.95	-0.9	0.78	-0.96	0.61	-0.88	0.61	0.98	-0.97		0.61	-0.97	-0.9	-0.95	0.61	0.99	-0.86	-0.47	-0.91	-0.93
Non Currrent Assets Other	-0.95	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.55	0.38	-0.47	1.0	-0.32	1.0	0.59	-0.48	0.61		-0.48	-0.46	-0.55	1.0	0.49	-0.65	-0.89	-0.39	-0.61
Cash And Short Term Investments	0.56	0.33	0.97	-0.73	0.73	0.86	1.0	0.86	-0.79	1.0	-0.48	0.94	-0.48	-0.99	1.0	-0.97	-0.48		0.92	0.9	-0.48	-0.98	0.81	0.31	0.96	0.92
Common Stock Total Equity	0.56	0.34	0.95	-0.76	0.8	0.62	0.91	0.9	-0.85	0.91	-0.46	0.83	-0.46	-0.91	0.92	-0.9	-0.46	0.92		0.87	-0.46	-0.91	0.79	0.32	0.93	0.96
Common Stock Shares Outstanding	0.66	0.56	0.84	-0.87	0.88	0.64	0.89	0.98	-0.72	0.9	-0.55	0.73	-0.55	-0.89	0.9	-0.95	-0.55	0.9	0.87		-0.55	-0.94	0.96	0.55	0.8	0.84
Short Term Investments	-0.95	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.55	0.38	-0.47	1.0	-0.32	1.0	0.59	-0.48	0.61	1.0	-0.48	-0.46	-0.55		0.49	-0.65	-0.89	-0.39	-0.61
Non Current Liabilities Total	-0.54	-0.36	-0.95	0.77	-0.8	-0.8	-0.98	-0.9	0.8	-0.98	0.49	-0.91	0.49	0.98	-0.98	0.99	0.49	-0.98	-0.91	-0.94	0.49		-0.83	-0.35	-0.94	-0.92
Other Stockholder Equity	0.8	0.73	0.72	-0.93	0.86	0.53	0.79	0.96	-0.62	0.8	-0.65	0.57	-0.65	-0.8	0.81	-0.86	-0.65	0.81	0.79	0.96	-0.65	-0.83		0.73	0.65	0.74
Total Liab	0.92	1.0	0.26	-0.84	0.72	0.03	0.26	0.57	-0.2	0.3	-0.89	0.05	-0.89	-0.39	0.31	-0.47	-0.89	0.31	0.32	0.55	-0.89	-0.35	0.73		0.14	0.37
Net Invested Capital	0.42	0.16	0.99	-0.63	0.68	0.8	0.95	0.77	-0.83	0.96	-0.39	0.97	-0.39	-0.96	0.96	-0.91	-0.39	0.96	0.93	0.8	-0.39	-0.94	0.65	0.14		0.95
Property Plant And Equipment Gross	0.62	0.4	0.98	-0.8	0.84	0.63	0.89	0.84	-0.84	0.91	-0.61	0.87	-0.61	-0.95	0.92	-0.93	-0.61	0.92	0.96	0.84	-0.61	-0.92	0.74	0.37	0.95

Click cells to compare fundamentals

Reviva Pharmaceuticals Account Relationship Matchups

Reviva Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	(123.0K)	(683.3K)	1.3M	(1.0M)	13.3M	14.0M
Total Current Liabilities	6.8M	1.3M	2.3M	6.0M	17.2M	18.0M
Net Tangible Assets	(35.9M)	7.4M	28.7M	12.3M	14.2M	14.9M
Retained Earnings	(54.5M)	(58.3M)	(66.8M)	(91.2M)	(134.4M)	(127.6M)
Accounts Payable	224.5K	1.0M	509.6K	3.5M	3.8M	4.0M
Total Current Assets	193.0	8.8M	31.4M	18.9M	23.7M	15.2M

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:

How To Invest In Reviva

Details

Is Reviva Stock a good investment?

Details

What is Reviva Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.08)

Return On Assets

(2.34)

Return On Equity

(17.95)

The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Reviva Non Current Liabilities Total vs Cash And Short Term Investments Analysis

Non Current Liabilities Total vs Cash And Short Term Investments

Non Current Liabilities Total vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Cash And Short Term Investments

Reviva Pharmaceuticals fundamental ratios Correlations

Reviva Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Reviva Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Total Assets	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments
Non Current Liabilities Total	- 0.98	Cash
Non Current Liabilities Total	- 0.98	Total Assets